deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT02394535

Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer

Combining Abraxane With Capecitabine and Radiation Therapy for Consolidation of Treatment Following Induction Chemotherapy for Locally Advanced Pancreatic Cancer

Sponsor: M.D. Anderson Cancer Center

Conditions Borderline Resectable Pancreatic Adenocarcinoma Locally Advanced Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma Stage II Pancreatic Cancer AJCC v6 and v7 Stage IIA Pancreatic Cancer AJCC v6 and v7 Stage IIB Pancreatic Cancer AJCC v6 and v7 Stage III Pancreatic Cancer AJCC v6 and v7
Interventions Capecitabine Laboratory Biomarker Analysis Nab-paclitaxel Questionnaire Administration Radiation Therapy
Updated 14 times since 2017 Last updated: Aug 31, 2022 Started: Nov 12, 2015 Primary completion: Aug 31, 2022 Completion: Aug 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Borderline Resectable Pancreatic Adenocarcinoma and Locally Advanced Pancreatic Adenocarcinoma, this trial is completed. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 14 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Aug 2019 · 7 months · monthly snapshot~Aug 2019 – ~Feb 2020 · 6 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Mar 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1

▶ Show 9 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Feb 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Aug 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

  4. Jan 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  5. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  6. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  7. May 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  8. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE1

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations